224 related articles for article (PubMed ID: 34151238)
21.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
22. The epigenetic promotion of osteogenic differentiation of human adipose-derived stem cells by the genetic and chemical blockade of histone demethylase LSD1.
Ge W; Liu Y; Chen T; Zhang X; Lv L; Jin C; Jiang Y; Shi L; Zhou Y
Biomaterials; 2014 Jul; 35(23):6015-25. PubMed ID: 24794925
[TBL] [Abstract][Full Text] [Related]
23. The transcriptional corepressor CBFA2T3 inhibits all-
Steinauer N; Guo C; Zhang J
J Biol Chem; 2020 Jul; 295(27):8887-8900. PubMed ID: 32434928
[TBL] [Abstract][Full Text] [Related]
24. Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells.
Liu L; Liu L; Leung LH; Cooney AJ; Chen C; Rosengart TK; Ma Y; Yang J
J Biol Chem; 2015 Apr; 290(17):10599-609. PubMed ID: 25737450
[TBL] [Abstract][Full Text] [Related]
25. LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C/EBPα.
Kohrogi K; Hino S; Sakamoto A; Anan K; Takase R; Araki H; Hino Y; Araki K; Sato T; Nakamura K; Nakao M
Blood Adv; 2021 May; 5(9):2305-2318. PubMed ID: 33929501
[TBL] [Abstract][Full Text] [Related]
26. Targeting the GFI1/1B-CoREST Complex in Acute Myeloid Leukemia.
van Bergen MGJM; van der Reijden BA
Front Oncol; 2019; 9():1027. PubMed ID: 31649884
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of O-GlcNAcase Inhibits Hematopoietic and Leukemic Stem Cell Self-Renewal and Drives Dendritic Cell Differentiation via STAT3/5 Signaling.
Luanpitpong S; Rodboon N; Samart P; Janan M; Klaihmon P; Lorthongpanich C; U-Pratya Y; Issaragrisil S
Stem Cells; 2022 Dec; 40(12):1078-1093. PubMed ID: 36124999
[TBL] [Abstract][Full Text] [Related]
28. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
[TBL] [Abstract][Full Text] [Related]
29. Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A).
Li Z; Ding L; Li Z; Wang Z; Suo F; Shen D; Zhao T; Sun X; Wang J; Liu Y; Ma L; Zhao B; Geng P; Yu B; Zheng Y; Liu H
Acta Pharm Sin B; 2019 Jul; 9(4):794-808. PubMed ID: 31384539
[TBL] [Abstract][Full Text] [Related]
30. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
Ishikawa Y; Gamo K; Yabuki M; Takagi S; Toyoshima K; Nakayama K; Nakayama A; Morimoto M; Miyashita H; Dairiki R; Hikichi Y; Tomita N; Tomita D; Imamura S; Iwatani M; Kamada Y; Matsumoto S; Hara R; Nomura T; Tsuchida K; Nakamura K
Mol Cancer Ther; 2017 Feb; 16(2):273-284. PubMed ID: 27903753
[TBL] [Abstract][Full Text] [Related]
31. Antagonistic actions of Rcor proteins regulate LSD1 activity and cellular differentiation.
Upadhyay G; Chowdhury AH; Vaidyanathan B; Kim D; Saleque S
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8071-6. PubMed ID: 24843136
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
33. PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia.
Curtiss BM; VanCampen J; Macaraeg J; Kong GL; Taherinasab A; Tsuchiya M; Yashar WM; Tsang YH; Horton W; Coleman DJ; Estabrook J; Lusardi TA; Mills GB; Druker BJ; Maxson JE; Braun TP
Leukemia; 2022 Jul; 36(7):1781-1793. PubMed ID: 35590033
[TBL] [Abstract][Full Text] [Related]
34. Guanosine primes acute myeloid leukemia for differentiation via guanine nucleotide salvage synthesis.
Wang H; He X; Li Z; Jin H; Wang X; Li L
Am J Cancer Res; 2022; 12(1):427-444. PubMed ID: 35141027
[TBL] [Abstract][Full Text] [Related]
35. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-
Smitheman KN; Severson TM; Rajapurkar SR; McCabe MT; Karpinich N; Foley J; Pappalardi MB; Hughes A; Halsey W; Thomas E; Traini C; Federowicz KE; Laraio J; Mobegi F; Ferron-Brady G; Prinjha RK; Carpenter CL; Kruger RG; Wessels L; Mohammad HP
Haematologica; 2019 Jun; 104(6):1156-1167. PubMed ID: 30514804
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia.
Fobare S; Elgamal OA; Wunderlich M; Stahl E; Mehmood A; Furby C; Lerma JR; Sesterhenn TM; Pan J; Rai J; Johnstone ME; Abdul-Aziz A; Johnson ML; Rai SN; Byrd JC; Hertlein E
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339323
[TBL] [Abstract][Full Text] [Related]
37. NUP98-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid-committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression.
Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Vargas MT; García-Lozano JR; Falantes JF; Prats-Martín C; Bernal R; Pérez-Simón JA
Int J Lab Hematol; 2016 Feb; 38(1):64-71. PubMed ID: 26418229
[TBL] [Abstract][Full Text] [Related]
38. Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
Braun TP; Coblentz C; Curtiss BM; Coleman DJ; Schonrock Z; Carratt SA; Callahan RL; Maniaci B; Druker BJ; Maxson JE
Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13670-13679. PubMed ID: 32471953
[TBL] [Abstract][Full Text] [Related]
39. HBO1 is required for the maintenance of leukaemia stem cells.
MacPherson L; Anokye J; Yeung MM; Lam EYN; Chan YC; Weng CF; Yeh P; Knezevic K; Butler MS; Hoegl A; Chan KL; Burr ML; Gearing LJ; Willson T; Liu J; Choi J; Yang Y; Bilardi RA; Falk H; Nguyen N; Stupple PA; Peat TS; Zhang M; de Silva M; Carrasco-Pozo C; Avery VM; Khoo PS; Dolezal O; Dennis ML; Nuttall S; Surjadi R; Newman J; Ren B; Leaver DJ; Sun Y; Baell JB; Dovey O; Vassiliou GS; Grebien F; Dawson SJ; Street IP; Monahan BJ; Burns CJ; Choudhary C; Blewitt ME; Voss AK; Thomas T; Dawson MA
Nature; 2020 Jan; 577(7789):266-270. PubMed ID: 31827282
[TBL] [Abstract][Full Text] [Related]
40. A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.
Wass M; Göllner S; Besenbeck B; Schlenk RF; Mundmann P; Göthert JR; Noppeney R; Schliemann C; Mikesch JH; Lenz G; Dugas M; Wermke M; Röllig C; Bornhäuser M; Serve H; Platzbecker U; Foerster KI; Burhenne J; Haefeli WE; Müller LP; Binder M; Pabst C; Müller-Tidow C;
Leukemia; 2021 Mar; 35(3):701-711. PubMed ID: 32561840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
